NCT03229525

Brief Summary

Post-traumatic Stress Disorder (PTSD) is a debilitating mental disorder that affects approximately 7% of the general population. This project's aim is to develop a greater understanding of the efficacy and underlying mechanisms of narrative exposure based treatments for PTSD. Adult participants (N=162) who meet DSM-5 criteria for PTSD will be enrolled in a 3-arm randomized clinical trial consisting of trauma-related expressive writing, trauma-related expressive speaking, or a factual expressive writing control condition. Treatments will be manualized and conducted entirely through the Qualtrics survey platform. Treatment will consist of six sessions, three per week over two weeks, taking place via the internet. Assessments will be conducted pre-treatment, post-treatment, and at 1-month follow-up in the lab. Assessments will be comprised of symptom self-report measures as well as two tasks completed in an eye tracker: a reading task to evaluate mechanisms underlying trauma narrative processing and a sentence production task to evaluate attentional shifts when producing verbal information Specific Aims and Hypotheses:

  1. 1.Develop and test the relative efficacy of two cost-effective internet-based expressive trauma therapies (written vs. spoken) relative to a non-trauma writing control for PTSD. We hypothesize that both trauma-focused expressive therapies will achieve more favorable outcomes at posttreatment and follow-up on measures of PTSD and depression symptoms, posttraumatic growth, and quality of life compared to the writing control.
  2. 2.Conduct exploratory analyses testing baseline PTSD severity, depression severity, trauma type, time since trauma, and emotional engagement in moderating the differential effects of the selected expressive therapies.
  3. 3.Test the moderation of (1) active language processing with eye tracking (i.e. how long certain words are fixated on). (2) selected linguistic elements (i.e., frequency of emotional words, frequency of the pronoun "I"), (3) perceived self-efficacy to cope with trauma memories; (4) perceived threat appraisals associated with intrusive trauma memories on treatment outcome at follow-up. We hypothesize that (1) fewer and shorter fixations on ideographic (i.e. personally relevant) trauma words when reading the trauma narrative in the eye tracker will be associated with reductions in PTSD symptoms at follow-up. (2) increased use of emotional words over the course of writing sessions will be associated with reductions in PTSD and depression symptoms at follow-up; (3) pre- to posttreatment increases in trauma memory acceptance self-efficacy; and (4) pre- to posttreatment reductions in trauma memory threat appraisals will be associated with greater symptom reduction at the follow-up assessment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
162

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 19, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 25, 2017

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2017

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2021

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2021

Completed
Last Updated

December 13, 2019

Status Verified

December 1, 2019

Enrollment Period

3.4 years

First QC Date

July 19, 2017

Last Update Submit

December 11, 2019

Conditions

Outcome Measures

Primary Outcomes (5)

  • Change in PTSD symptom severity

    PTSD Symptom Checklist at each assessment

    Pre-treatment (baseline), Post-treatment (2-weeks), Follow-up (1 month, 3 months, 6 months)

  • Change in Depression symptoms

    Becks Depression Inventory at each assessment

    Pre-treatment (baseline), Post-treatment (2-weeks), Follow-up (1 month)

  • Change in Posttraumatic Growth

    Post Traumatic Growth Inventory at each assessment

    Pre-treatment (baseline), Post-treatment (2-weeks), Follow-up (1 month)

  • Change in Reading Task indices

    Reading narratives in an eye tracker at each assessment

    Pre-treatment (baseline), Post-treatment (2-weeks), Follow-up (1 month)

  • Change in Sentence Production Task indices

    Describing images in an eye tracker at each assessment

    Pre-treatment (baseline), Post-treatment (2-weeks), Follow-up (1 month)

Study Arms (2)

Trauma Related Expressive Writing

ACTIVE COMPARATOR

Participants randomized to this condition will complete six sessions during which they will write about their trauma for 20 minutes. The participant will receive instructions to write about the traumatic event that they feel affects them the most. For each session they will be instructed to write about the same event. For the first session, participants will complete psychoeducation and treatment rationale modules. The instructions for writing about the traumatic event will emphasize the importance of exploring their deepest emotions and thoughts at the time of the event, as well as providing detailed information about the event itself. For the remaining five writing sessions participants will be instructed to write about the same event and to focus on providing a detailed description of the part of the event that was most distressing to them, as well as how the event had affected their lives. A researcher will review the writing independently to ensure treatment compliance.

Behavioral: Trauma Related Expressive Writing

Neutral Expressive Writing

SHAM COMPARATOR

Participants randomized to this condition will complete six sessions during which they will write about their day, without describing emotions or opinions. Previous research has shown a significant reduction of symptoms with this type of control writing condition in participants with PTSD (Sloan et al., 2011). A researcher will review the writing to ensure compliance.

Behavioral: Neutral Expressive Writing

Interventions

Participants will write about the traumatic event over the course of six sessions.

Trauma Related Expressive Writing

Participants will write about a neutral event over the course of six sessions.

Neutral Expressive Writing

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males or females between the ages of 18 and 65
  • Meets Diagnostic and Statistical Manual 5 criteria for PTSD
  • Able to give consent
  • Access to a computer in a private place
  • Completes initial writing samples online

You may not qualify if:

  • Impaired vision
  • Bipolar Disorder
  • Psychosis
  • Suicidality
  • Current trauma related treatment
  • Psychotropic medication \<2 months or not stable (dosage variable) in past 2 months
  • Reading grade level \> 6th grade level
  • Obsessive Compulsive Disorder
  • Traumatic Brain Injury

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Laboratory for the Study of Anxiety Disorders

Austin, Texas, 78712, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Stress Disorders, Post-Traumatic

Condition Hierarchy (Ancestors)

Stress Disorders, TraumaticTrauma and Stressor Related DisordersMental Disorders

Study Officials

  • Michael Telch, Phd

    University of Texas at Austin

    PRINCIPAL INVESTIGATOR
  • Mikael Rubin, MA

    University of Texas at Austin

    STUDY DIRECTOR

Central Study Contacts

Michael Telch, PhD

CONTACT

Mikael Rubin, MA

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

July 19, 2017

First Posted

July 25, 2017

Study Start

September 1, 2017

Primary Completion

February 1, 2021

Study Completion

September 1, 2021

Last Updated

December 13, 2019

Record last verified: 2019-12

Data Sharing

IPD Sharing
Will not share

Locations